Methodology

UK regulatory methodology

How we approach UK peptide regulation across the site. Which primary sources we use, what we will write and what we will not, and why nothing here is legal advice.

Primary sources we rely on

For any UK regulatory statement, we work back to a primary source. Where a primary link is not yet verified, the page renders a [TODO: verify URL] placeholder rather than guessing.

UK & international primary sources

MHRA — Medicines and Healthcare products Regulatory Agency — gov.uk
The UK regulator for medicines and medical devices. Source for licensed status, Drug Safety Updates, and counterfeit-medicine warnings.
NICE — National Institute for Health and Care Excellence — nice.org.uk
UK technology appraisals and clinical guidelines that drive NHS access decisions.
NHS — nhs.uk
Patient-facing NHS information. Useful for plain-English medicine summaries and access routes.
EMA — European Medicines Agency — ema.europa.eu
EU regulator. Relevant for product information, EMA scientific assessments, and EU safety updates.
WADA Prohibited List — wada-ama.org
The current list of substances and methods prohibited in sport.
UK Anti-Doping (UKAD) — ukad.org.uk
UK enforcement of WADA rules. Source for athlete guidance.
Human Medicines Regulations 2012 (UK) — legislation.gov.uk
Consolidated UK regulations governing medicinal products.
Yellow Card — MHRA adverse reaction reporting — yellowcard.mhra.gov.uk
How UK patients and clinicians report suspected side effects.
General Pharmaceutical Council (GPhC) register — pharmacyregulation.org
Register of UK pharmacies and pharmacists outside Northern Ireland.
Pharmaceutical Society of Northern Ireland (PSNI) register — psni.org.uk
Register of pharmacies and pharmacists in Northern Ireland.

What we will write

• Whether a compound is, or is not, a licensed medicine in the UK at the time of writing.
• Whether a compound is treated as a prescription-only medicine (UK POM) when used as a medicine.
• Whether NICE has issued a technology appraisal or guideline that bears on the compound's NHS use.
• Whether the MHRA has issued safety updates, alerts, or counterfeit warnings about a product class.
• Whether the compound is on the WADA Prohibited List or commonly treated as prohibited under S0.
• How marketing claims relate to the Human Medicines Regulations and advertising rules.

What we will not write

• Whether a specific person can lawfully buy, import, store, possess, or use a compound — that depends on individual facts and is a legal question for a qualified solicitor.
• Whether a specific seller, clinic, or pharmacy is operating lawfully.
• Predictions about future MHRA, NICE, or EMA decisions.
• Advice on how to interact with HMRC, Border Force, or regulators.
• How to evade anti-doping testing or counterfeit detection.

Key concepts we use consistently

Licensed medicine: A medicine with a UK marketing authorisation (formerly “product licence”) allowing it to be sold and used for a defined indication. Held by the MHRA.
Prescription-only medicine (UK POM): A medicine that can only be supplied against a valid prescription from an appropriately registered prescriber and dispensed by a regulated UK pharmacy.
Unlicensed compound: A substance with no UK marketing authorisation for human use. Many “research peptides” fall here. Marketing them with human-use claims raises serious regulatory issues.
“Research use only” / “not for human consumption”: A labelling convention used by some sellers. The MHRA looks at the context and intended purpose of supply, not only the label. Adding “research use only” does not by itself make human-use marketing lawful.
Compounded / compounding pharmacy: A regulated pharmacy that prepares a specific medicine for a specific patient under specific conditions. Not the same as bulk grey-market peptide supply.
Strict liability (sport): Under WADA / UKAD rules, athletes are responsible for what is in their bodies. Contamination, mislabelling, or unknown ingredients do not generally excuse a positive test.

Last reviewed: 15 May 2026

Next review due: 15 May 2027

Spotted an error or something out of date? Send a correction.

Primary sources we rely on

For any UK regulatory statement, we work back to a primary source. Where a primary link is not yet verified, the page renders a [TODO: verify URL] placeholder rather than guessing.

UK & international primary sources

MHRA — Medicines and Healthcare products Regulatory Agency — gov.uk
The UK regulator for medicines and medical devices. Source for licensed status, Drug Safety Updates, and counterfeit-medicine warnings.
NICE — National Institute for Health and Care Excellence — nice.org.uk
UK technology appraisals and clinical guidelines that drive NHS access decisions.
NHS — nhs.uk
Patient-facing NHS information. Useful for plain-English medicine summaries and access routes.
EMA — European Medicines Agency — ema.europa.eu
EU regulator. Relevant for product information, EMA scientific assessments, and EU safety updates.
WADA Prohibited List — wada-ama.org
The current list of substances and methods prohibited in sport.
UK Anti-Doping (UKAD) — ukad.org.uk
UK enforcement of WADA rules. Source for athlete guidance.
Human Medicines Regulations 2012 (UK) — legislation.gov.uk
Consolidated UK regulations governing medicinal products.
Yellow Card — MHRA adverse reaction reporting — yellowcard.mhra.gov.uk
How UK patients and clinicians report suspected side effects.
General Pharmaceutical Council (GPhC) register — pharmacyregulation.org
Register of UK pharmacies and pharmacists outside Northern Ireland.
Pharmaceutical Society of Northern Ireland (PSNI) register — psni.org.uk
Register of pharmacies and pharmacists in Northern Ireland.

What we will write

• Whether a compound is, or is not, a licensed medicine in the UK at the time of writing.

• Whether a compound is treated as a prescription-only medicine (UK POM) when used as a medicine.

• Whether NICE has issued a technology appraisal or guideline that bears on the compound's NHS use.

• Whether the MHRA has issued safety updates, alerts, or counterfeit warnings about a product class.

• Whether the compound is on the WADA Prohibited List or commonly treated as prohibited under S0.

• How marketing claims relate to the Human Medicines Regulations and advertising rules.

What we will not write

• Whether a specific person can lawfully buy, import, store, possess, or use a compound — that depends on individual facts and is a legal question for a qualified solicitor.

• Whether a specific seller, clinic, or pharmacy is operating lawfully.

• Predictions about future MHRA, NICE, or EMA decisions.

• Advice on how to interact with HMRC, Border Force, or regulators.

• How to evade anti-doping testing or counterfeit detection.

Key concepts we use consistently

Licensed medicine

A medicine with a UK marketing authorisation (formerly “product licence”) allowing it to be sold and used for a defined indication. Held by the MHRA.

Prescription-only medicine (UK POM)

A medicine that can only be supplied against a valid prescription from an appropriately registered prescriber and dispensed by a regulated UK pharmacy.

Unlicensed compound

A substance with no UK marketing authorisation for human use. Many “research peptides” fall here. Marketing them with human-use claims raises serious regulatory issues.

“Research use only” / “not for human consumption”

A labelling convention used by some sellers. The MHRA looks at the context and intended purpose of supply, not only the label. Adding “research use only” does not by itself make human-use marketing lawful.

Compounded / compounding pharmacy

A regulated pharmacy that prepares a specific medicine for a specific patient under specific conditions. Not the same as bulk grey-market peptide supply.

Strict liability (sport)

Under WADA / UKAD rules, athletes are responsible for what is in their bodies. Contamination, mislabelling, or unknown ingredients do not generally excuse a positive test.